Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517062 · ClinicalTrials.gov registry record · Early Phase 1
Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates
A Early Phase 1 study of Growth Hormone Deficiency, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00517062 is a Early Phase 1 study of Growth Hormone Deficiency that has completed, run by Oregon Health and Science University. The registered enrollment target is 16 participants, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00517062, a Early Phase 1 study of Growth Hormone Deficiency, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Study hypothesis: Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity in adults with GH deficiency. Study aims: The purpose of this study is to determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) in adults with GH deficiency. Study design: Men and women with confirmed GH deficiency, but not recently been on GH treatment will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participating in the study. If suitable, an equal number of men and women will be randomized to receive either low dose GH or placebo injection for 3 months. Before, during and after treatment, the subjects will be assessed at regularly with blood tests, scans and fat biopsies. At the first and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of IGF-I in the muscle; whereas blood tests to examine insulin sensitivity will also be collected. This study will use Genotropin and Genotropin pen devices, and the the data will be analyzed using a computer statistical program where the identity of the subjects will be coded to maintain confidentiality.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Growth hormone (Genotropin)
Study Locations (1)
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517062
The ClinicalTrials.gov registry entry for NCT00517062 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (96% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00517062 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00517062 about?
NCT00517062 is a clinical study titled "Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates". Study hypothesis: Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity in adults with GH deficiency. Study aims: The purpose of this study is to determine the mechanism of how low dose GH treatment affects the body'...
What is the current status of trial NCT00517062?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2006-01. Estimated completion is 2012-01.
What conditions does trial NCT00517062 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency.
What interventions are being tested in trial NCT00517062?
The interventions under investigation include: Placebo (DRUG), Growth hormone (Genotropin) (DRUG).
Who is sponsoring clinical trial NCT00517062?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00517062 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
RECRUITING
-
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
RECRUITING
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Chromosome 18 Clinical Research Center
RECRUITING
-
Growth Hormone Replacement Therapy for Retried Professional Football Players
RECRUITING · Phase 2
-
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.